POSITION: Clinical Researcher, Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
WORK EXPERIENCE:
November 2020 onwards: Research Fellow, Department of Neurosciences, Drug and Child Health, University of Florence, Florence, Italy.
Jan 2019 -Dec 2019: Visiting researcher, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London UK.
Oct 2018 – Oct 2020: Clinical research fellow, Department of Neurosciences, University of Florence, Italy. Clinical and research activities in the Multiple Sclerosis Regional Referral Centre for Tuscany, Careggi University Hospital, Florence, Italy.
Neurology outpatient clinics, Italian National Healthcare System.
Aug 2013 – Aug 2018: Medical training in neurology, University of Florence, Italy. Research activities in the experimental program of autologous hematopoietic stem cells transplantation in aggressive forms of Multiple Sclerosis, in collaboration with the Hematological Department of Careggi University Hospital, Florence, Italy.
Study investigator in the following clinical studies: WANT (observational study regarding Work Ability in NaTalizumab Treated patients); multicenter observational study regarding Fingolimod administration Safety.
Nov 2011 – Aug 2012: Internship in Neuroimmunology Laboratory (chief Prof Clara Ballerini), Dept. of neurosciences - University of Florence.
EDUCATION:
Mother tongue: Italian.
Other language: English, level B2.
PUBLICATIONS:
Mariottini, A., De Matteis, E., Cencioni, M. T., & Muraro, P. A. (2023). Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances. Current Neurology and Neuroscience Reports, 1-14.
Mariottini, A., Muraro, P. A., & Saccardi, R. (2023). Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 104932.
Mariottini, A., Lotti, A., Innocenti, C., Repice, A. M., Nozzoli, C., Boncompagni, R., ... & Massacesi, L. (2023). Effect of COVID‐19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation. European Journal of Neurology.
Lotti A, Barilaro A, Mariottini A, Vannozzi L, Piergentili M, Fainardi E and Massacesi L (2023) Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management. Front. Neurol. 14:1201643. doi: 10.3389/fneur.2023.1201643
Bertozzi, A., Mariottini, A., Marchi, L., Di Cristinzi, M., Nistri, R., Damato, V., ... & Repice, A. M. (2023). Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclero-sis: a monocentric experience. Multiple Sclerosis and Related Disorders, 104582.
Mariottini, A., Bulgarini, G., Cornacchini, S., Damato, V., Saccardi, R., & Massacesi, L. (2023). Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update. Bioengineering, 10(2), 176.
Boffa, G., Signori, A., Massacesi, L., Mariottini, A., Sbragia, E., Cottone, S., ... & Inglese, M. (2023). Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. Neurology, 100(11), e1109-e1122.
Mariottini A, Muraro PA, Lünemann JD. Antibody-mediated cell depletion therapies in multiple sclerosis. Front Immunol. 2022 Sep 12;13:953649. doi: 10.3389/fimmu.2022.953649. PMID: 36172350; PMCID: PMC9511140.
Massacesi, L., Mariottini, A., & Nicoletti, F. (2022). Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. Journal of Clinical Medicine, 11(15), 4288.
Amoriello, R., Rizzo, R., Mariottini, A., Bortolotti, D., Gentili, V., Bonechi, E., ... & Ballerini, C. (2022). Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis. Frontiers in neurology, 13.
Farina, A., Falso, S., Cornacchini, S., Spagni, G., Monte, G., Mariottini, A., ... & Damato, V. (2022). Safety and tolerability of SARS‐Cov2 vaccination in patients with myasthenia gravis: a multicenter experience. European Journal of Neurology.
Mariottini A, Marchi L, Innocenti C, Di Cristinzi M, Pasca M, Filippini S, … & Repice AM (2022) Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. Front. Neurol. 13:820256. doi: 10.3389/fneur.2022.820256
Mariottini, A., Bulgarini, G., Forci, B., Innocenti, C., Mealli, F., Mattei, A., ... & Massacesi, L. (2022). Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis. European Journal of Neurology.
Mariottini, A., Bertozzi, A., Marchi, L., Di Cristinzi, M., Mechi, C., Barilaro, A., ... & Repice, A. M. (2022). Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. Journal of Neurology, 1-8.
Mariottini, A., Forci, B., Gualdani, E., Romoli, M., Repice, A. M., Barilaro, A., ... & Francesconi, P. (2022). Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. Multiple Sclerosis and Related Disorders, 60, 103679.
Mariottini, A., Repice, A. M., Barilaro, A., & Massacesi, L. (2022). Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance. Neurological Sciences, 1-3.
Mariottini, A., Filippini, S., Innocenti, C., Forci, B., Mechi, C., Barilaro, A., ... & Repice, A. M. (2021). Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 27(1), 61-70.
Mariottini, A., De Matteis, E., & Muraro, P. A. (2020). Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status. BioDrugs, 1-19.
Mariottini, A., Innocenti, C., Forci, B., Magnani, E., Mechi, C., Barilaro, A., ... & Repice, A. M. (2019). Safety and efficacy of autologous hematopoietic stem‐cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis. European journal of neurology, 26(4), 624-630.
Amoriello, R., Mariottini, A., & Ballerini, C. (2021). Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis. Frontiers in immunology, 12.
Nicholas, R. S., Rhone, E. E., Mariottini, A., Silber, E., Malik, O., Singh-Curry, V., ... & Muraro, P. (2021). Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series. Neurology, 97(9), e890-e901.
Boffa, G., Massacesi, L., Inglese, M., Mariottini, A., Capobianco, M., Moiola, L., ... & Mancardi, G. (2021). Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 96(8), e1215-e1226.
Amoriello, R., Greiff, V., Aldinucci, A., Bonechi, E., Carnasciali, A., Peruzzi, B., ... & Massacesi, L. (2020). The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. Frontiers in immunology, 11, 559.
Signori, A., Boffa, G., Bovis, F., Mariottini, A., Repice, A., Inglese, M., ... & Sormani, M. P. (2020). Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. Multiple Sclerosis Journal, 1352458520936236.
Pasca, M., Forci, B., Mariottini, A., Mechi, C., Barilaro, A., Massacesi, L., & Repice, A. M. (2020). Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Multiple sclerosis and related disorders, 47, 102591.
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. Forci, B., Mariottini, A., Mechi, C., Massacesi, L., & Repice, A. (2017). Multiple sclerosis and related disorders, 15, 24-26.
Legenda
